## the Market Trendsaa

The global immunofluorescence assay market size is growing pervasively. The market growth attributes to the increase in biological studies in R&D for the detection of biomolecules like glycans, proteins, and small biological and non-biological molecules of various diseases. Also, immunofluorescence assays are primarily used for rapid and sensitive diagnostics of various chronic diseases such as cancer, autoimmune diseases, infectious diseases like HIV, neurological disorders such as Alzheimer's and Parkinson's diseases.

With the intervention of the COVID-19, the immunofluorescence assay industry overview is witnessing a massive demand across the globe. This is due to the rising usages of immunofluorescence assays in the development of antibodies that can detect sars-Cov-2 in patient samples. According to Market Research Future (MRFR), the global Immunofluorescence Assay Market is expected to reach USD 2.7 Billion by 2030 at 6.10% CAGR during the forecast period 2022-2030.

Advancements in medical technology, alongside the increasing R&D funding by industry leaders and governments, boost the market growth. Additionally, rising numbers of preclinical research, alongside the rising studies on antibody therapies, advanced <u>drug discoveries</u>, and oncology diseases, accelerate the market growth. Growing collaborations between research institutes and biotechnology companies are expected to drive the growth of the immunofluorescence assay market.

Conversely, the high cost of immunofluorescence assay products such as diagnostic kits is expected to restrict the market growth during the forecast period. Also, factors such as risks of cross contaminations and shortage of skilled labor & weak detection signals are estimated to impede the growth of this market. Nevertheless, growing advancements in biotechnology & medical science would support the growth of the market, bringing about cost-effective immunofluorescence assay.

Global Immunofluorescence Assay Market – Competitive Analysis

Highly competitive, the global <u>immunofluorescence assay market</u> appears fragmented due to the presence of several well-established players. To gain a larger competitive advantage, players incorporate strategies such as mergers & acquisitions, collaborations, expansion, and product/technology launch. Top players make huge investments for R&D and clinical trials to develop these assays. Pharmaceutical companies are the largest investors in the immunofluorescence assay market.

## Major Players:

The global immunofluorescence assay market Players leading include Abcam plc., Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc., BioTek Instruments, Inc., Bio-Rad Laboratories, Inc., Zyagen Cell Signaling Technology, Inc., PerkinElmer Inc., Becton Dickinson and Company, Merck, Agilent Technologies, TCS Biosciences Ltd, and Maxvision Biosciences Inc., among others.

Global Immunofluorescence Assay Market – Segmentation

The report is segmented into five dynamics;

By Technique: Primary (Direct) Immunofluorescence Assays and Secondary (Indirect) Immunofluorescence Assays (Salt split technique, Antigenic mapping method, Double Staining method), Micro Immunofluorescence.

By Product Type: Antibodies, Kits & Reagents, Instruments, Microscopes, Imaging Analysis Systems, Labeling dyes, Species Product Type, and others.

By Application: Clinical Research, Clinical Diagnostics, Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Neurological Diseases, Research & Development, and others.

By End-User: Biotechnology Companies, Hospitals & Research Institutes, Contract Research Organizations, Diagnostic centers, and others.

By Regions: Americas, Europe, Asia Pacific, and Rest-of-the-World.

Global Immunofluorescence Assay Market – Regional Analysis

